CCDC171

Summary

CCDC171 (coiled-coil domain containing 171, HGNC:29828) is a protein-coding gene on chromosome 9p22.3, encoding Coiled-coil domain-containing protein 171 (Q6TFL3).

At a glance

• GWAS associations: 19
• Clinical variants (ClinVar): 285 total — 2 pathogenic
• MANE Select transcript: NM_173550

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:29828
Approved symbol	CCDC171
Name	coiled-coil domain containing 171
Location	9p22.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ39267, FLJ46740, Em:AL513423.1, bA778P13.1, bA536D16.1
Ensembl gene	ENSG00000164989
Ensembl biotype	protein_coding
Entrez	203238

Gene structure

Transcript identifiers

Ensembl transcripts: 15 — 9 protein_coding, 6 protein_coding_CDS_not_defined

ENST00000380701, ENST00000432954, ENST00000449575, ENST00000470191, ENST00000472806, ENST00000474193, ENST00000478913, ENST00000486641, ENST00000498725, ENST00000905141, ENST00000905142, ENST00000971281, ENST00000971282, ENST00000971283, ENST00000971284

RefSeq mRNA: 3 — MANE Select: NM_173550 NM_001348002, NM_001355547, NM_173550

CCDS: CCDS6481

Canonical transcript exons

ENST00000380701 — 26 exons

Exon	Start	End
ENSE00001375592	15723681	15723746
ENSE00001485960	15971609	15974037
ENSE00001593272	15591366	15591556
ENSE00001622649	15784509	15784694
ENSE00001629436	15594041	15594172
ENSE00001660066	15721769	15721875
ENSE00001666873	15695235	15695337
ENSE00001676962	15657127	15657219
ENSE00001692861	15678758	15678896
ENSE00001699809	15729610	15729798
ENSE00001703357	15571624	15571759
ENSE00001714455	15778968	15779150
ENSE00001731532	15727869	15728036
ENSE00001757779	15724776	15724976
ENSE00001758615	15666163	15666323
ENSE00001768167	15777600	15777826
ENSE00001773495	15745515	15745631
ENSE00001777958	15744273	15744777
ENSE00001784391	15623267	15623413
ENSE00001798754	15578849	15579023
ENSE00001920616	15553043	15553302
ENSE00002733524	15563978	15564129
ENSE00003527544	15920270	15920422
ENSE00003553657	15846702	15846847
ENSE00003630949	15848893	15848947
ENSE00003670854	15874532	15874663

Expression profiles

Bgee: expression breadth ubiquitous, 181 present calls, max score 88.08.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 3.2349 / max 142.0891, expressed in 1131 samples.

FANTOM5 promoters (10 alternative TSS)

Promoter ID	TPM avg	Samples expressed
96151	0.9841	500
96152	0.7335	441
96150	0.5666	260
96153	0.3707	150
205434	0.2087	68
96154	0.1711	64
96159	0.1317	14
96149	0.0408	7
96155	0.0183	3
96160	0.0095	3

Top tissues by expression

239 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	88.08	gold quality
left testis	UBERON:0004533	87.97	gold quality
right testis	UBERON:0004534	87.34	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	86.46	gold quality
testis	UBERON:0000473	85.91	gold quality
right uterine tube	UBERON:0001302	84.12	gold quality
body of uterus	UBERON:0009853	83.63	gold quality
cortical plate	UBERON:0005343	82.90	gold quality
sperm	CL:0000019	82.26	gold quality
calcaneal tendon	UBERON:0003701	81.19	gold quality
smooth muscle tissue	UBERON:0001135	79.82	gold quality
tibial nerve	UBERON:0001323	79.34	gold quality
sural nerve	UBERON:0015488	79.17	gold quality
buccal mucosa cell	CL:0002336	78.43	gold quality
ventricular zone	UBERON:0003053	77.96	gold quality
right hemisphere of cerebellum	UBERON:0014890	77.34	gold quality
cerebellar hemisphere	UBERON:0002245	76.81	gold quality
cerebellar cortex	UBERON:0002129	76.63	gold quality
ganglionic eminence	UBERON:0004023	75.22	gold quality
cerebellum	UBERON:0002037	74.79	gold quality
tendon	UBERON:0000043	74.35	gold quality
right frontal lobe	UBERON:0002810	73.77	gold quality
myometrium	UBERON:0001296	73.17	gold quality
left ovary	UBERON:0002119	73.00	gold quality
Brodmann (1909) area 9	UBERON:0013540	72.55	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	72.35	gold quality
tibial artery	UBERON:0007610	72.19	gold quality
popliteal artery	UBERON:0002250	72.18	gold quality
adrenal tissue	UBERON:0018303	72.10	gold quality
anterior cingulate cortex	UBERON:0009835	71.70	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.95
E-CURD-112	no	2.91

Regulation

Is transcription factor: no

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Ccdc171	ENSMUSG00000052407
rattus_norvegicus	AABR07049060.1	ENSRNOG00000033445

Protein

Protein identifiers

Coiled-coil domain-containing protein 171 — Q6TFL3 (reviewed: Q6TFL3)

All UniProt accessions (3): Q6TFL3, H0Y5M5, H0Y701

UniProt curated annotations — full annotation on UniProt →

Isoforms (3)

UniProt ID	Names	Canonical?
Q6TFL3-1	1	yes
Q6TFL3-3	2
Q6TFL3-4	3

RefSeq proteins (3): NP_001334931, NP_001342476, NP_775821* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR038820	CCDC171	Family

UniProt features (21 total): coiled-coil region 8, sequence variant 5, splice variant 3, sequence conflict 3, chain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6TFL3-F1	71.56	0.04

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 59 (showing top): CGGAARNGGCNG_UNKNOWN, GGCKCATGS_UNKNOWN, MYB_Q3, JAATINEN_HEMATOPOIETIC_STEM_CELL_UP, RIGGI_EWING_SARCOMA_PROGENITOR_UP, MYB_Q5_01, TGGAAA_NFAT_Q4_01, SCGGAAGY_ELK1_02, MGGAAGTG_GABP_B, GSE14415_NATURAL_TREG_VS_FOXP3_KO_NATURAL_TREG_DN, GSE13547_WT_VS_ZFX_KO_BCELL_ANTI_IGM_STIM_12H_DN, ARID5B_TARGET_GENES, FOXD2_TARGET_GENES, HES2_TARGET_GENES, NFE2L1_TARGET_GENES

GO Biological Process (0):

GO Molecular Function (0):

GO Cellular Component (0):

Protein interactions and networks

STRING

570 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CCDC171	TTC39B	Q5VTQ0	516
CCDC171	SNAPC3	Q92966	475
CCDC171	DEPP1	Q9NTK1	459
CCDC171	FREM1	Q5H8C1	448
CCDC171	ZNF654	Q8IZM8	419
CCDC171	DENND4C	Q5VZ89	409
CCDC171	CCDC190	Q86UF4	404
CCDC171	CCDC74B	Q96LY2	400
CCDC171	CCDC169	A6NNP5	400
CCDC171	IGSF22	Q8N9C0	384
CCDC171	CLCN3	P51790	381
CCDC171	CCL5	P13501	377
CCDC171	IL17A	Q16552	377
CCDC171	IL13	P35225	375
CCDC171	CCL3	P10147	375

IntAct

5 interactions, top by confidence:

A	B	Type	Score
CCDC171	S100A10	psi-mi:“MI:0915”(physical association)	0.400
CCDC171	HSP90B1	psi-mi:“MI:0915”(physical association)	0.400
CRY1	IGKV2D-30	psi-mi:“MI:0914”(association)	0.350
CSNK2B	TUBAL3	psi-mi:“MI:0914”(association)	0.350

BioGRID (11): CCDC171 (Synthetic Lethality), CCDC171 (Affinity Capture-RNA), CCDC171 (Proximity Label-MS), CCDC171 (Proximity Label-MS), CCDC171 (Affinity Capture-MS), CCDC171 (Affinity Capture-MS), CCDC171 (Cross-Linking-MS (XL-MS)), C12orf45 (Cross-Linking-MS (XL-MS)), PCM1 (Cross-Linking-MS (XL-MS)), CCDC171 (Affinity Capture-MS), CCDC171 (Affinity Capture-RNA)

ESM2 similar proteins: A2AIV8, A2AL36, A2AM05, A3KNA5, A6PWD2, B1AJZ9, B2RZ86, B9V5F5, E9Q1U1, O35550, O35551, P0CAP1, P27628, P55937, Q08DR9, Q0IHN7, Q0VF96, Q15276, Q19UN5, Q29RS0, Q4L180, Q5BIX7, Q5R923, Q6AW69, Q6NRC9, Q6P6L0, Q6PHN1, Q6TFL3, Q70FJ1, Q7YS99, Q7Z7A1, Q7Z7B0, Q861Q8, Q86SQ7, Q8BI22, Q8K3K8, Q8K4T4, Q8N998, Q8R5M4, Q95JI9

Diamond homologs: E9Q1U1, Q6TFL3

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

285 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	0
Uncertain significance	253
Likely benign	10
Benign	3

Top pathogenic / likely-pathogenic (2)

Variant ID	HGVS	Classification
2685337	GRCh37/hg19 9p24.1-22.3(chr9:8595338-15622555)x1	Pathogenic
562131	GRCh37/hg19 9p23-22.2(chr9:13563537-18491752)x1	Pathogenic

SpliceAI

6939 predictions. Top by Δscore:

Variant	Effect	Δscore
9:15578847:A:AG	acceptor_gain	1.0000
9:15578847:AGCT:A	acceptor_gain	1.0000
9:15578848:G:GG	acceptor_gain	1.0000
9:15578848:GCTG:G	acceptor_gain	1.0000
9:15579021:GTG:G	donor_gain	1.0000
9:15591364:A:AG	acceptor_gain	1.0000
9:15591365:G:GG	acceptor_gain	1.0000
9:15591365:GCACA:G	acceptor_gain	1.0000
9:15591474:A:T	donor_gain	1.0000
9:15623261:TTCCA:T	acceptor_loss	1.0000
9:15623262:TCCA:T	acceptor_loss	1.0000
9:15623263:CCA:C	acceptor_loss	1.0000
9:15623264:CA:C	acceptor_loss	1.0000
9:15623265:AGG:A	acceptor_loss	1.0000
9:15623266:G:A	acceptor_loss	1.0000
9:15623412:AGG:A	donor_loss	1.0000
9:15623414:GT:G	donor_loss	1.0000
9:15623415:T:A	donor_loss	1.0000
9:15657125:A:AG	acceptor_gain	1.0000
9:15657126:G:GG	acceptor_gain	1.0000
9:15666153:C:A	acceptor_gain	1.0000
9:15666157:C:A	acceptor_gain	1.0000
9:15666161:A:AG	acceptor_gain	1.0000
9:15666162:G:GG	acceptor_gain	1.0000
9:15666162:GTTAC:G	acceptor_gain	1.0000
9:15666319:AATTT:A	donor_gain	1.0000
9:15666320:ATTT:A	donor_gain	1.0000
9:15666321:TTT:T	donor_gain	1.0000
9:15666321:TTTG:T	donor_loss	1.0000
9:15666322:TT:T	donor_gain	1.0000

AlphaMissense

8814 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
9:15846714:G:C	A1094P	0.998
9:15779038:G:C	R990P	0.997
9:15784686:G:C	A1087P	0.997
9:15846727:T:C	L1098P	0.997
9:15846757:T:C	L1108P	0.997
9:15846769:T:C	L1112P	0.997
9:15846819:G:C	A1129P	0.996
9:15657193:T:C	S297P	0.995
9:15657199:T:C	F299L	0.995
9:15657201:T:A	F299L	0.995
9:15657201:T:G	F299L	0.995
9:15666179:T:C	L311P	0.995
9:15846748:T:C	L1105P	0.995
9:15657181:G:C	A293P	0.994
9:15666167:G:C	R307P	0.994
9:15846706:T:C	L1091P	0.994
9:15846832:T:C	L1133P	0.993
9:15920382:T:C	L1238P	0.993
9:15779017:T:C	L983P	0.992
9:15779047:T:C	L993P	0.992
9:15846799:T:C	L1122P	0.992
9:15657178:G:C	A292P	0.991
9:15779041:G:C	R991P	0.991
9:15784552:T:C	L1042P	0.991
9:15784560:G:C	A1045P	0.991
9:15784615:T:C	L1063P	0.991
9:15846751:G:C	R1106P	0.991
9:15846778:T:C	L1115P	0.991
9:15578913:G:C	R81P	0.990
9:15657177:A:C	R291S	0.990

dbSNP variants (sampled 300 via entrez): RS1000003196 (9:15616333 A>C), RS1000006938 (9:15570734 G>C,T), RS1000011310 (9:15564004 C>T), RS1000012147 (9:16040107 A>G), RS1000013986 (9:15771578 T>A,C), RS1000016648 (9:16040483 G>A,T), RS1000018221 (9:15600644 C>G), RS1000019925 (9:16103869 C>A,G,T), RS1000020068 (9:15935994 A>G), RS1000020705 (9:16006316 T>C,G), RS1000028710 (9:15788411 T>A,C), RS1000031473 (9:15878578 C>G,T), RS1000031857 (9:15622251 A>G), RS1000032086 (9:16006089 T>C), RS1000032279 (9:15713546 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Mondo (3): prostate cancer (MONDO:0008315), intellectual disability (MONDO:0001071), isolated oxycephaly (MONDO:0018971)

Orphanet (3): Familial prostate cancer (Orphanet:1331), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658), OBSOLETE: Isolated oxycephaly (Orphanet:63440)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

19 associations (top):

Study	Trait	p-value
GCST002783_134	Body mass index	5.000000e-09
GCST002783_319	Body mass index	6.000000e-09
GCST002783_600	Body mass index	9.000000e-07
GCST004904_43	Body mass index	3.000000e-10
GCST007325_260	General risk tolerance (MTAG)	3.000000e-09
GCST008129_49	Body mass index	1.000000e-10
GCST008154_72	Trunk fat mass	6.000000e-06
GCST008157_40	Body fat mass	4.000000e-07
GCST008550_7	Mental health study participation (completed survey)	3.000000e-08
GCST010133_1	Lamb consumption	1.000000e-15
GCST010141_2	Beef consumption	4.000000e-10
GCST010143_16	Meat-related diet	4.000000e-17
GCST010143_8	Meat-related diet	5.000000e-12
GCST010988_391	Adult body size	2.000000e-19
GCST010989_146	Body size at age 10	2.000000e-09
GCST011704_9	Smoking status (current vs never)	3.000000e-08
GCST011742_53	Triglyceride levels in HIV infection	4.000000e-06
GCST012317_11	Triglyceride levels x SSRI levels (escitalopram or citalopram) interaction in schizophrenia or bipolar disorder	7.000000e-06
GCST90000025_464	Appendicular lean mass	7.000000e-14

EFO canonical traits (8, from GWAS)

EFO ID	Trait name
EFO:0004340	body mass index
EFO:0008579	risk-taking behaviour
EFO:0010130	health study participation
EFO:0008111	diet measurement
EFO:0009819	comparative body size at age 10, self-reported
EFO:0006527	smoking status measurement
EFO:0004530	triglyceride measurement
EFO:0004980	appendicular lean mass

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

38 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
methyleugenol	decreases expression	1
triphenyl phosphate	affects expression	1
bisphenol A	decreases methylation, affects cotreatment	1
ethyl-p-hydroxybenzoate	decreases expression	1
trichostatin A	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	increases expression	1
sodium arsenite	decreases expression	1
butyraldehyde	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
pentanal	decreases expression	1
perfluorooctane sulfonic acid	increases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
abrine	decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Glyphosate	decreases expression	1
Atrazine	decreases expression	1
Benzo(a)pyrene	decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Diethylhexyl Phthalate	decreases expression	1
Lipopolysaccharides	decreases expression, affects response to substance, increases expression	1
Melphalan	decreases expression	1
Methotrexate	increases expression	1
Nickel	decreases expression	1
Potassium Dichromate	decreases expression	1
Tetrachlorodibenzodioxin	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer